Clinical Trial Update: A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating two combinations of IDH-mutant targeted therapies plus azacitidine in newly diagnosed AML patients who are not candidates for intensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Enasidenib (enasidenib)
• Ivosidenib (ivosidenib)

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-11-22